ASH 2019 | Transcend NHL 001: liso-cel in R/R B-cell NHL
David Maloney
• 7 Dec 2019
David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, outlines the results of the Transcend NHL 001 study (NCT02631044). This is a phase I study in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) receiving lisocabtagene maraleucel, an investigational, anti-CD19, defined composition, 4-1BB, CAR T-cell product administered at a target dose of CD4+ and CD8+ CAR T-cells. Dr Maloney talks about the use of this CAR-T product in the outpatient setting, the future perspectives for this agent and patient-reported outcomes. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
